

# **TOBIRA THERAPEUTICS, INC.**

## **FORM 15-12B**

(Termination of Registration of a Class of Security under Section 12(b))

Filed 11/14/16

Address	701 GATEWAY BLVD SUITE 300 SOUTH SAN FRANCISCO, CA 94080
Telephone	650-741-6625
CIK	0001311596
Symbol	TBRA
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Medical Research
Sector	Healthcare
Fiscal Year	12/31

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 15**

---

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION  
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934  
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Commission File Number: 001-35953

---

**TOBIRA THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

---

701 Gateway Blvd, Suite 300  
South San Francisco, CA 94080  
(650) 741-6625

(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

Common Stock, \$0.001 par value  
(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

---

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)	<input checked="" type="checkbox"/>
Rule 12g-4(a)(2)	<input type="checkbox"/>
Rule 12h-3(b)(1)(i)	<input checked="" type="checkbox"/>
Rule 12h-3(b)(1)(ii)	<input type="checkbox"/>
Rule 15d-6	<input type="checkbox"/>

Approximate number of holders of record as of the certification or notice date: One\*

\* On November 1, 2016 pursuant to the Agreement and Plan of Merger, dated as of September 19, 2016, by and among Allergan Holdco US, Inc. ("Allergan Holdco"), a Delaware corporation and direct wholly owned subsidiary of Allergan plc, an Irish public limited company ("Allergan"), Sapphire Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of Allergan ("Purchaser") and Tobira Therapeutics, Inc., a Delaware corporation ("Tobira"), Purchaser merged with and into Tobira, with Tobira being the surviving entity (the "Merger"). As a result of the Merger, Tobira became an indirect wholly owned subsidiary of Allergan.

Pursuant to the requirements of the Securities Exchange Act of 1934, Tobira Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

TOBIRA THERAPEUTICS, INC.

Date: November 14, 2016

By: /s/ A. R. OBERT D. B AILEY  
A. Robert D. Bailey  
President, Director

---

---